stockrowRoyalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
- Revenue
- +13.3%
- EPS
- −51.5%
- Free cash flow
- +364.6%
- Total debt
- −4.00%
Quarter to September 2026, against a year earlier
Follow RPRX
Alert me
Royalty Pharma PLC (RPRX) Free cash flow
Royalty Pharma PLC's free cash flow for fiscal 2025 was $2.5B, down 9.49% from $2.8B in fiscal 2024. Over the twelve months to 30 September 2026 it was $3.0B. Over the past ten years it has ranged from −$174.0M (fiscal 2021) to $3.0B (fiscal 2023); the current reading is higher than 75% of that period. Royalty Pharma PLC ranks 3rd of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $2.5B | (9.49%) |
| FY2024 | $2.8B | (7.93%) |
| FY2023 | $3.0B | 40.75% |
| FY2022 | $2.1B | — |
| FY2021 | −$174.0M | — |
| FY2020 | −$147.6M | — |
| FY2019 | −$54.1M | — |
| FY2018 | $1.3B | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $686.1M | 43.70% |
| Jun 2026 | $477.4M | 79.58% |
| Mar 2026 | $265.9M | (67.86%) |
| Dec 2025 | $827.1M | — |
| 27 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| RPRX Royalty Pharma PLC | $3.0B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.4B |
| ARGX argenex SE compare | $1.4B |
| INCY Incyte Corporation compare | $679.9M |
| BNTX BioNTech SE Sponsored ADR compare | −$524.1M |
| INSM Insmed, Inc. compare | −$627.6M |
| ROIV Roivant Sciences Ltd. compare | −$821.1M |
| RVMD Revolution Medicines, Inc. compare | −$1.4B |
| GMAB Genmab A/S Sponsored ADR compare | −$6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on RPRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement